OncoMatch/Clinical Trials/NCT06050317
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Is NCT06050317 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sintilimab Plus mFFN or NALIRIFOX and Radiation for pancreas cancer.
Treatment: Sintilimab Plus mFFN or NALIRIFOX and Radiation — Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
Cannot have received: systemic anti-tumor therapy
patients who have not received systemic anti-tumor therapy
Cannot have received: Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects
systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9 cells/L, platelets ≥ 75 × 10^9 cells/L, hemoglobin ≥ 9.0 g/dl
Kidney function
creatinine ≤ 1.5 × ULN
Liver function
AST < 2.5 × ULN, ALT < 2.5 × ULN, total bilirubin ≤ 1.5 × ULN
Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl; AST<2.5 × ULN, ALT<2.5 × ULN, creatinine ≤1.5xULN, total bilirubin ≤1.5 X ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06050317 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages